IP Library Granted Patent US 10,799,138
Granted Patent B2
US 10,799,138 · App. 16/376,706 · Granted Oct 13, 2020

Method of administering sotalol IV/switch

Inventors: Vijay Ivaturi (Baltimore, MD); Jogarao Gobburu (Herndon, VA)
Assignee: University of Maryland, Baltimore
A61B5/046A61K9/0019A61K9/0053A61K31/18G16H50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,799,138
App. No.
16/376,706
Granted
Oct 13, 2020
Kind
B2
Abstract

Embodiments of the invention are broadly drawn to methods for determining an optimum dose of an antiarrhythmic drug, for example sotalol. In particular, the method involves titrating the dose of the drug gradually to determine the optimum plasma concentration for a patient, whether the patient has normal or abnormal renal function.

Claims (16)

1. A method comprising:

1) detecting a baseline QTc of a subject;

2) administering a dose of sotalol to the subject via an intravenous infusion for a duration of time, then

3) determining the difference between the baseline QTc and QTc measured after the intravenous infusion to detect a delta QTc,

4) determining that the delta QTc is not in an acceptable range of less than 20% from the baseline QTc, and

5) discontinuing intravenous administration to the subject and administering at least one further dose orally.

2. The method of claim 1 , wherein the subject has normal or abnormal renal function and the dose of sotalol administered via the intravenous infusion is 10 mg 60 mg.

3. The method of claim 1 , wherein the duration of time is 0.5 hour-2 hours.

4. The method of claim 1 , wherein the subject has normal or abnormal renal function, and, and wherein the at least one further dose comprises 75 mg, 80 mg, 120 mg, or 160 mg sotalol, and wherein the at least one further dose is administered orally 0.5 to 2 hours after the start of the intravenous infusion.

5. The method of claim 1 , wherein when the subject has normal renal function, a maintenance dose of at least 80 mg sotalol is orally administered 12 hours from initiation of the intravenous infusion, and every 12 hours thereafter.

6. The method of claim 1 , wherein when the subject has abnormal renal function, a maintenance dose of at least 80 mg sotalol is orally administered 24 hours from initiation of the intravenous infusion, and every 24 hours thereafter.

7. The method of claim 5 , wherein the maintenance dose is 120 mg of sotalol.

8. The method of claim 6 , wherein the maintenance dose is 120 mg of sotalol.

9. The method of claim 1 , wherein the subject has normal renal function and a maintenance dose of sotalol is orally administered once every 12 hours after IV infusion is terminated.

10. The method of claim 1 , wherein the subject has abnormal renal function and a maintenance dose of sotalol is orally administered once every 24 hours after IV infusion is terminated.

11. The method of claim 2 , wherein the dose administered via the intravenous infusion is 40 mg sotalol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2019
From: IVATURI, VIJAY; GOBBURU, JOGARAO
To: UNIV. OF MARYLAND, BALTIMORE
Reel/Frame 048990/0246 →
Continuity (2)
Provisional Application 62652943 · Apr 5, 2018
Related Publication 20190307343A1 · Oct 10, 2019
Cited By (4)
US 12,390,431 US 12,396,970 US 12,403,109 US 12,740,947